Perrigo
PRGOPRGO · Stock Price
Historical price data
Overview
Perrigo's mission is to make lives better by providing trusted, accessible health and wellness solutions to all. The company has evolved from its 1887 origins into a multinational enterprise with a core strategy of delivering value through private-label manufacturing and select branded products. Its achievements include building a robust, diversified portfolio in essential self-care categories and maintaining a resilient supply chain. Perrigo's strategy focuses on expanding its self-care portfolio, driving operational excellence, and leveraging its formulation and regulatory expertise to capitalize on the growing demand for affordable healthcare.
Technology Platform
A vertically-integrated commercialization, formulation, and supply chain platform focused on efficient development, manufacturing, and distribution of bioequivalent OTC drugs, infant nutrition, and consumer health products.
Pipeline
7| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Vivomixx + Placebo | Breast Cancer | Phase 1/2 | |
| Famotidine Tablets, 40 mg | Bioavailability | Phase 1 | |
| Naproxen Tablets, 500 mg | Bioequivalency | Phase 1 | |
| Ibuprofen Tablets, 800 mg | Bioequivalency | Phase 1 | |
| Naproxen Tablets, 500 mg | Bioequivalency | Phase 1 |
Funding History
2FDA Approved Drugs
49Opportunities
Risk Factors
Competitive Landscape
Perrigo competes with branded giants (J&J, Bayer, GSK) in consumer health and with large generic manufacturers (Teva, Viatris) in private label. Its hybrid model of owning brands and manufacturing for retailers is its primary differentiator.
Company Timeline
Founded in Dublin, Ireland
Initial Public Offering
Debt: $800.0M
FDA Approval: FEXOFENADINE HYDROCHLORIDE
FDA Approval: NASONEX 24HR ALLERGY
FDA Approval: GUAIFENESIN AND PSEUDOEPHEDRINE HYDROCHLORIDE